This company listing is no longer active
Ergomed Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
CEO
Ergomed has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.3yrs | UK£964.30k | 17.53% € 141.0m | |
| Chief Transformation & Technology Officer | 1yr | UK£52.77k | no data | |
| CFO & Executive Director | less than a year | no data | no data | |
| Head of Risk Management & Pharmacoepidemiology | 5.5yrs | no data | no data | |
| President of PrimeVigilance | no data | no data | no data | |
| President of Clinical Research | no data | no data | no data | |
| Senior Vice President of Global Development | 2yrs | no data | no data | |
| Senior Vice-President of Capital Markets & Strategy | 1.8yrs | no data | no data | |
| Company Secretary | 4.2yrs | no data | no data |
2.0yrs
Average Tenure
62yo
Average Age
Experienced Management: 2EM's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.3yrs | UK£964.30k | 17.53% € 141.0m | |
| CFO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 2.4yrs | UK£52.72k | no data | |
| Independent Non-Executive Director | 2.6yrs | UK£52.72k | no data | |
| Independent Non-Executive Director | 1.4yrs | UK£27.89k | no data | |
| Senior Independent Director | 1.7yrs | UK£49.15k | no data |
2.0yrs
Average Tenure
61yo
Average Age
Experienced Board: 2EM's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/14 19:02 |
| End of Day Share Price | 2023/11/10 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ergomed plc is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Colin Grant | Davy |
| Jonas Peciulis | Edison Investment Research |